Statins for chemoprevention of hepatocellular carcinoma: Assessing the evidence

Expert Review of Gastroenterology and Hepatology

Volumn 7, Issue 6, 2013, Pages 493-495

  Siegel, Abby B ^a   El Serag, Hashem B ^a  

^a NONE   (United States)

Author keywords

hepatocellular carcinoma; prevention; statin

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; PRAVASTATIN;

BREAST CANCER; CANCER PREVENTION; COLON CANCER; GENETIC POLYMORPHISM; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER FIBROSIS; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PROTEIN PROCESSING; REVIEW; RISK REDUCTION; TUMOR RECURRENCE;

ANTICARCINOGENIC AGENTS; CARCINOMA, HEPATOCELLULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; LIVER NEOPLASMS; PATIENT SELECTION; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84887832039     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2013.814884     Document Type: Review

References (35)

1. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J. Clin. Oncol. 27(9), 1485-1491 (2009).
2. Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J. Hepatol. 56(6), 1384-1391 (2012).
3. Mozumdar A, Liguori G. Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999-2006. Diabetes Care 34(1), 216-219 (2011).
4. Yeh CJ, Chang HY, Pan WH. Time trend of obesity, the metabolic syndrome and related dietary pattern in Taiwan: from NAHSIT 1993-1996 to NAHSIT 2005-2008. Asia Pac. J. Clin. Nutr. 20(2), 292-300 (2011).
5. Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer 115(24), 5651-5661 (2009).
6. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science 332(6037), 1519-1523 (2011).
7. Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology 54(2), 463-471 (2011).
8. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med. 348(17), 1625-1638 (2003). (Pubitemid 36459468)
9. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126(2), 460-468 (2004). (Pubitemid 38182303)
10. Ohki T, Tateishi R, Sato T et al. Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients. Clin. Gastroenterol. Hepatol. 6(4), 459-464 (2008). (Pubitemid 351443115)
11. Konishi I, Hiasa Y, Shigematsu S et al. Diabetes pattern on the 75 g oral glucose tolerance test is a risk factor for hepatocellular carcinoma in patients with hepatitis C virus. Liver Int. 29(8), 1194-1201 (2009).
12. Park EJ, Lee JH, Yu GY et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140(2), 197-208 (2010).
13. Siegel AB, Lim EA, Wang S et al. Diabetes, body mass index, and outcomes in hepatocellular carcinoma patients undergoing liver transplantation. Transplantation 94(5), 539-543 (2012).
14. Kapadia SB, Chisari FV. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc. Natl Acad. Sci. USA 102(7), 2561-2566 (2005). (Pubitemid 40279416)
15. Rao GA, Pandya PK. Statin therapy improves sustained virologic response among diabetic patients with chronic hepatitis C. Gastroenterology 140(1), 144-152 (2011).
16. Athyros VG, Tziomalos K, Gossios TD et al.; GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 376(9756), 1916-1922 (2010).
17. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat. Rev. Cancer 5(12), 930-942 (2005). (Pubitemid 41766782)
18. Weitz-Schmidt G, Welzenbach K, Brinkmann V et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. 7(6), 687-692 (2001). (Pubitemid 32588024)
19. Wu J, Wong WW, Khosravi F, Minden MD, Penn LZ. Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Res. 64(18), 6461-6468 (2004). (Pubitemid 39297901)
20. Bonovas S, Filioussi K, Tsavaris N, Sitaras NM. Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J. Clin. Oncol. 23(34), 8606-8612 (2005). (Pubitemid 46211502)
21. Poynter JN, Gruber SB, Higgins PD et al. Statins and the risk of colorectal cancer. N. Engl. J. Med. 352(21), 2184-2192 (2005). (Pubitemid 40727085)
22. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N. Engl. J. Med. 367(19), 1792-1802 (2012).
23. Bonovas S, Filioussi K, Flordellis CS, Sitaras NM. Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients. J. Clin. Oncol. 25(23), 3462-3468 (2007). (Pubitemid 47310884)
24. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a meta-analysis. JAMA 295(1), 74-80 (2006). (Pubitemid 43042692)
25. El-Serag HB, Johnson ML, Hachem C, Morgana RO. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology 136(5), 1601-1608 (2009).
26. Tsan YT, Lee CH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J. Clin. Oncol. 30(6), 623-630 (2012).
27. Wu CY, Chen YJ, Ho HJ et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA 308(18), 1906-1914 (2012).
28. Kawata S, Yamasaki E, Nagase T et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br. J. Cancer 84(7), 886-891 (2001). (Pubitemid 32385829)
29. Graf H, Jüngst C, Straub G et al. Chemoembolization combined with pravastatin improves survival in patients with hepatocellular carcinoma. Digestion 78(1), 34-38 (2008).
30. Tsan YT, Lee CH, Ho WC, Lin MH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection. J. Clin. Oncol. 31(12), 1514-1521 (2013).
31. Henderson LM, Patel S, Giordano TP, Green L, El-Serag HB. Statin therapy and serum transaminases among a cohort of HCV-infected veterans. Dig. Dis. Sci. 55(1), 190-195 (2010).
32. Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology 144(2), 323-332 (2013).
33. Valenti L, Rumi M, Galmozzi E et al. Patatin-like phospholipase domaincontaining 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology 53(3), 791-799 (2011).
34. Burza MA, Pirazzi C, Maglio C et al. PNPLA3 I148M (rs738409) genetic variant is associated with hepatocellular carcinoma in obese individuals. Dig. Liver Dis. 44(12), 1037-1041 (2012).
35. Lipkin SM, Chao EC, Moreno V et al. Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer. Cancer Prev. Res. (Phila.) 3(5), 597-603 (2010).